Ranitidine is used to reduce the amount of acid the stomach makes and also in the treatment of acid reflux and stomach or ...

Drug regulator DCGI has asked drug controllers of all states and Union Territories to direct manufacturers under their jurisdiction to monitor the presence of a potentially carcinogenic chemical — ...

Manufacturers have been asked to adopt risk-based approaches, including stricter testing protocols, revised storage ...

The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services, has issued a ...

CDSCO is monitoring ranitidine due to NDMA, a potential carcinogen. The DTAB recommended a study on the drug's safety, ...

NDMA is classified as a Group 2A carcinogen by the International Agency for Research on Cancer (IARC), indicating it is a ...

The Central Drugs Standard Control Organisation has flagged concerns of a cancer-causing impurity in Ranitidine -- a commonly ...

The Central Drugs Standard Control Organisation (CDSCO) has directed all state and union territory drug regulators to ensure ...

An announcement from Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) is now available. On July 25, 2025, Incannex Healthcare Inc. announced ...